Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
Background: The double-blind, 2 × 2 factorial design, placebo-controlled ASCEND randomized trial compared the effects of 100 mg aspirin daily and, separately, 1 g omega-3 fatty acids (FAs) daily on the primary prevention of cardiovascular disease in 15,480 UK adults with diabetes. We report the effe...
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Journal article |
| Jezik: | English |
| Izdano: |
BioMed Central
2024
|
| _version_ | 1826315174111346688 |
|---|---|
| author | Sammons, EL Buck, G Bowman, LJ Stevens, WM Hammami, I Parish, S Armitage, J |
| author_facet | Sammons, EL Buck, G Bowman, LJ Stevens, WM Hammami, I Parish, S Armitage, J |
| author_sort | Sammons, EL |
| collection | OXFORD |
| description | Background: The double-blind, 2 × 2 factorial design, placebo-controlled ASCEND randomized trial compared the effects of 100 mg aspirin daily and, separately, 1 g omega-3 fatty acids (FAs) daily on the primary prevention of cardiovascular disease in 15,480 UK adults with diabetes. We report the effects of these randomized treatment allocations on scores derived from the National Eye Institute’s Visual Function Questionnaire-25 (NEI-VFQ-25) in a subset of participants involved in the ASCEND-Eye sub-study. Methods: Ordinal data from the NEI-VFQ-25 were analyzed using proportional odds regression methods. A common odds ratio with a 95% confidence interval was used to interpret the average effect size of randomization to each study treatment on composite and subdomain scores from the questionnaire. Results: Neither randomization to aspirin nor omega-3 FAs for 7.5 years significantly affected composite or subdomain scores from the NEI-VFQ-25. Conclusion: Applying the NEI-VFQ-25 in ASCEND-Eye represents one of the largest surveys of vision-targeted health-related quality of life in people with diabetes. Further observational analyses of these data are planned, to identify the clinical and demographic characteristics associated with lower composite and subdomain scores in a diabetic population. Trial registration: Eudract No. 2004–000991-15; Multicentre Research Ethics Committee Ref No. 03/8/087 (29th December 2003); ClinicalTrials.gov No. NCT00135226 (24th August 2005); ISRCTN No. ISRCTN60635500 (1st September 2005). |
| first_indexed | 2024-12-09T03:20:49Z |
| format | Journal article |
| id | oxford-uuid:d73d27d7-a578-48c7-9904-6de24f7ded78 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:20:49Z |
| publishDate | 2024 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:d73d27d7-a578-48c7-9904-6de24f7ded782024-11-05T20:07:28ZEffects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d73d27d7-a578-48c7-9904-6de24f7ded78EnglishJisc Publications RouterBioMed Central2024Sammons, ELBuck, GBowman, LJStevens, WMHammami, IParish, SArmitage, JBackground: The double-blind, 2 × 2 factorial design, placebo-controlled ASCEND randomized trial compared the effects of 100 mg aspirin daily and, separately, 1 g omega-3 fatty acids (FAs) daily on the primary prevention of cardiovascular disease in 15,480 UK adults with diabetes. We report the effects of these randomized treatment allocations on scores derived from the National Eye Institute’s Visual Function Questionnaire-25 (NEI-VFQ-25) in a subset of participants involved in the ASCEND-Eye sub-study. Methods: Ordinal data from the NEI-VFQ-25 were analyzed using proportional odds regression methods. A common odds ratio with a 95% confidence interval was used to interpret the average effect size of randomization to each study treatment on composite and subdomain scores from the questionnaire. Results: Neither randomization to aspirin nor omega-3 FAs for 7.5 years significantly affected composite or subdomain scores from the NEI-VFQ-25. Conclusion: Applying the NEI-VFQ-25 in ASCEND-Eye represents one of the largest surveys of vision-targeted health-related quality of life in people with diabetes. Further observational analyses of these data are planned, to identify the clinical and demographic characteristics associated with lower composite and subdomain scores in a diabetic population. Trial registration: Eudract No. 2004–000991-15; Multicentre Research Ethics Committee Ref No. 03/8/087 (29th December 2003); ClinicalTrials.gov No. NCT00135226 (24th August 2005); ISRCTN No. ISRCTN60635500 (1st September 2005). |
| spellingShingle | Sammons, EL Buck, G Bowman, LJ Stevens, WM Hammami, I Parish, S Armitage, J Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial |
| title | Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial |
| title_full | Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial |
| title_fullStr | Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial |
| title_full_unstemmed | Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial |
| title_short | Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial |
| title_sort | effects of aspirin and omega 3 fatty acids on composite and subdomain scores from the nei vfq 25 questionnaire the ascend eye randomized controlled trial |
| work_keys_str_mv | AT sammonsel effectsofaspirinandomega3fattyacidsoncompositeandsubdomainscoresfromtheneivfq25questionnairetheascendeyerandomizedcontrolledtrial AT buckg effectsofaspirinandomega3fattyacidsoncompositeandsubdomainscoresfromtheneivfq25questionnairetheascendeyerandomizedcontrolledtrial AT bowmanlj effectsofaspirinandomega3fattyacidsoncompositeandsubdomainscoresfromtheneivfq25questionnairetheascendeyerandomizedcontrolledtrial AT stevenswm effectsofaspirinandomega3fattyacidsoncompositeandsubdomainscoresfromtheneivfq25questionnairetheascendeyerandomizedcontrolledtrial AT hammamii effectsofaspirinandomega3fattyacidsoncompositeandsubdomainscoresfromtheneivfq25questionnairetheascendeyerandomizedcontrolledtrial AT parishs effectsofaspirinandomega3fattyacidsoncompositeandsubdomainscoresfromtheneivfq25questionnairetheascendeyerandomizedcontrolledtrial AT armitagej effectsofaspirinandomega3fattyacidsoncompositeandsubdomainscoresfromtheneivfq25questionnairetheascendeyerandomizedcontrolledtrial |